{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:12:32Z","timestamp":1780366352178,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12886-017-0611-3","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T04:12:31Z","timestamp":1512101551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Bilateral uveitis and macular edema induced by Nivolumab: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Claire","family":"Theillac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Breton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"issue":"4","key":"611_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"611_CR2","first-page":"215","volume":"4","author":"G Schmid-Bindert","year":"2015","unstructured":"Schmid-Bindert G, Jiang T. First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and \u2018the sorcerers apprentice. Transl Lung Cancer Res. 2015;4(3):215\u20136.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"611_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433\u201340.","journal-title":"JAMA Oncol"},{"issue":"6","key":"611_CR4","first-page":"571","volume":"30","author":"D Day","year":"2016","unstructured":"Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs Clin Immunother Biopharm Gene Ther. 2016;30(6):571\u201384.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"9","key":"611_CR5","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391.","journal-title":"J Clin Invest"},{"issue":"26","key":"611_CR6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"611_CR7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related Pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373(3):288\u201390.","journal-title":"N Engl J Med"},{"key":"611_CR8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","volume":"7","author":"G Della Vittoria Scarpati","year":"2014","unstructured":"Della Vittoria Scarpati G, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets Ther. 2014;7:203\u20139.","journal-title":"OncoTargets Ther"},{"issue":"2","key":"611_CR9","first-page":"140","volume":"24","author":"E Papavasileiou","year":"2016","unstructured":"Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo A-M. Ipilimumab-induced ocular and orbital inflammation--a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140\u20136.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"611_CR10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0042-102668","volume":"233","author":"FC Fierz","year":"2016","unstructured":"Fierz FC, Meier F, Chaloupka K, B\u00f6ni C. Intraocular inflammation associated with new therapies for Cutaneous melanoma - case series and review. Klin Monatsbl Augenheilkd. 2016;233(4):540\u20134.","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"1","key":"611_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-014-0041-1","volume":"2","author":"JS Manusow","year":"2014","unstructured":"Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer. 2014;2(1):41.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"611_CR12","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5301\/ejo.5000724","volume":"26","author":"K Abu Samra","year":"2016","unstructured":"Abu Samra K, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26(3):e46\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"611_CR13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICB.0000000000000368","volume":"11","author":"MT Aaberg","year":"2016","unstructured":"Aaberg MT, Aaberg TM. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. 2016;11:348.","journal-title":"Retin Cases Brief Rep"},{"issue":"9","key":"611_CR14","first-page":"379","volume":"39","author":"S Diem","year":"2016","unstructured":"Diem S, et al. Pembrolizumab-triggered Uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother Hagerstown Md 1997. 2016;39(9):379\u201382.","journal-title":"J Immunother Hagerstown Md 1997"},{"issue":"11","key":"611_CR15","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1002\/phar.1839","volume":"36","author":"KS Hanna","year":"2016","unstructured":"Hanna KS. A rare case of Pembrolizumab-induced Uveitis in a patient with metastatic melanoma. Pharmacotherapy. 2016;36(11):e183\u20138.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"611_CR16","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jcjo.2015.09.008","volume":"51","author":"A Basilious","year":"2016","unstructured":"Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol J Can Ophtalmol. 2016;51(1):e4\u20136.","journal-title":"Can J Ophthalmol J Can Ophtalmol"},{"issue":"2","key":"611_CR17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.39406","volume":"68","author":"G de Velasco","year":"2016","unstructured":"de Velasco G, Bermas B, Choueiri TK. Autoimmune Arthropathy and Uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol Hoboken NJ. 2016;68(2):556\u20137.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"611_CR18","doi-asserted-by":"publisher","unstructured":"Karlin J, Gentzler R, Golen J. Bilateral anterior Uveitis associated with Nivolumab therapy. Ocul Immunol Inflamm. 2016;1\u20133. doi: 10.1080\/09273948.2016.1215473.","DOI":"10.1080\/09273948.2016.1215473."},{"key":"611_CR19","doi-asserted-by":"publisher","unstructured":"T. Arai, K. Harada, Y. Usui, R. Irisawa, and R. Tsuboi, \u201cCase of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient,\u201d J. Dermatol. 2017;44(8):975\u20136. doi: 10.1111\/1346-8138.13612 . Epub 2016 Sept 21.","DOI":"10.1111\/1346-8138.13612"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-017-0611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T19:33:36Z","timestamp":1660073616000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-017-0611-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s12886-017-0611-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"227"}}